Drug intelligence / Profile preview

Euralka

Development stage: Unknown
Lead developer: S.P. Pharmaceuticals
Administration: Oral

Overview

Euralka is an Ayurvedic proprietary medicine developed by S.P. Pharmaceuticals, primarily used as a systemic and urinary alkalizer. Formulated as an oral syrup, it is indicated for the management of various urinary tract conditions, including burning micturition, urinary tract infections (UTIs), and renal calculi (kidney stones). The product leverages a polyherbal blend designed to normalize urinary pH, provide symptomatic relief from irritation, and assist in the flushing of stones and bacteria through its diuretic and lithontriptic properties. It is commonly marketed in India as a retail Ayurvedic product for renal and urinary health.

Brand names: Euralka
Other names: Euralka Syrup

Beyond the preview

Go deeper on Euralka.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Euralka.

Explore the full profile